指南与共识妇科肿瘤

欧洲专家共识:初治卵巢癌的BRCA/同源重组缺陷检测

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.
指南 / 共识 · Ann Oncol · 2021-12-01

该共识由欧洲多学科专家组采用改良Delphi流程制定,基于系统文献检索,最终98名照护者就34条陈述达成共识,聚焦BRCA1/2突变与HRR缺陷检测的适用时机与人群、开发更优HRR缺陷检测的重要性、胚系非BRCA HRR及错配修复基因突变对家族风险的预测价值而非一线PARPi敏感性预测,以及检测告知与照护者培训教育。

要点

  • 共识就34条陈述达成一致,涉及BRCA1/2及HRR缺陷检测的时机与适用人群。
  • 强调开发新的、更好的HRR缺陷检测方法的重要性。
  • 胚系非BRCA HRR及错配修复基因突变用于预测家族风险,不用于预测一线PARPi敏感性。

核心结论

  • 来自欧洲多学科专家组的共识推荐为初治晚期卵巢癌患者的BRCA及HRR缺陷检测使用提供了明确指导。

研究设计与样本

  • 欧洲专家共识组由指导委员会(n=14)和贡献者(n=84)组成,采用改良Delphi流程。
  • 共识声明基于按PRISMA指南进行的系统文献检索。
  • 最终98名照护者(包括肿瘤科医生、病理科医生、临床遗传学家、遗传学研究人员和患者倡导者)就34条陈述达成共识。

主要发现

  • HRR缺陷预计发生在大约一半的高级别浆液性卵巢癌中。
  • 携带HRR缺陷的卵巢癌通常对聚ADP核糖聚合酶抑制剂(PARPi)表现出敏感性。
  • 共识陈述集中于BRCA1/2突变检测和HRR缺陷检测的价值,包括检测时机和检测对象。
  • 共识陈述强调开发新的、更好的HRR缺陷检测方法的重要性。
  • 共识陈述强调胚系非BRCA HRR和错配修复基因突变对预测家族风险的重要性,但不用于预测一线治疗中PARPi的敏感性。

关键数值与推荐

  • 当前指南推荐一系列遗传检测方法,以识别卵巢癌中对PARPi敏感性的预测因素并识别遗传易感性。
  • 98名照护者就34条陈述达成共识。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR deficiency typically exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi). Current guidelines recommend a range of approaches for genetic testing to identify predictors of sensitivity to PARPi in ovarian cancer and to identify genetic predisposition. DESIGN: To establish a European-wide consensus for genetic testing (including the genetic care pathway), decision making and clinical management of patients with recently diagnosed advanced ovarian cancer, and the validity of biomarkers to predict the effectiveness of PARPi in the first-line setting. The collaborative European experts' consensus group consisted of a steering committee (n = 14) and contributors (n = 84). A (modified) Delphi process was used to establish consensus statements based on a systematic literature search, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. RESULTS: A consensus was reached on 34 statements amongst 98 caregivers (including oncologists, pathologists, clinical geneticists, genetic researchers, and patient advocates). The statements concentrated on (i) the value of testing for BRCA1/2 mutations and HRR deficiency testing, including when and whom to test; (ii) the importance of developing new and better HRR deficiency tests; (iii) the importance of germline non-BRCA HRR and mismatch repair gene mutations for predicting familial risk, but not for predicting sensitivity to PARPi, in the first-line setting; (iv) who should be able to inform patients about genetic testing, and what training and education should these caregivers receive. CONCLUSION: These consensus recommendations, from a multidisciplinary panel of experts from across Europe, provide clear guidance on the use of BRCA and HRR deficiency testing for recently diagnosed patients with advanced ovarian cancer.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Vergote I, González-Martín A, Ray-Coquard I, et al. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2021. PMID: 34861371. doi:10.1016/j.annonc.2021.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。